17 research outputs found
Behavior of Soil Reinforcements in Slopes
No full textAbstractIn geotechnical and transportation engineering, especially road constructions in cuts and deep excavation problems are solved by using different supporting excavation methods. Soil reinforcements are chosen due to easy and economic application. In this study, behavior of supported slopes with geotextiles and geogrids were analyzed by performing experiments on slope models in the laboratory. In the experiments, a static loading was applied to find failure surface and deformations for each case. Additionally, slopes were designed by using Plaxis program. At the end of the study, experimental and analytic models were compared and also behavior of models were presented
Determinants of optimal aerobic bioreactor landfilling for the treatment of the organic fraction of municipal waste
No full textHistorically, municipal solid waste landfills have been designed and operated as disposal facilities with suboptimal degradation under anaerobic conditions, resulting in slow waste stabilization and generation of landfill gas rich in methane and high strength leachate. Recently, aerobic bioreactor landfilling is being promoted as a promising method that enhances waste stabilization while producing a relatively weaker leachate and no methane generation. The authors review transformation processes and benefits associated with aerobic bioreactor landfilling. Factors affecting the operation of aerobic bioreactor landfills were detailed and performance indicators were defined with technical and operational considerations. The article emphasizes conditions for economic viability of the technology and concludes with outlining existing gaps and future research needs to improve the understanding and performance of aerobic bioreactor landfilling. © 2014 Copyright © Taylor and Francis Group, LLC.Abichou T, 2006, WASTE MANAGE, V26, P1305, DOI 10.1016-j.wasman.2005.11.016; Agadag O. N., 2005, CHEMOSPHERE, V59, P871; Agadag O. N., 2004, J ENV SCI HLTH A, V39, P2955; Alvarez-Vazquez H, 2004, J CHEM TECHNOL BIOT, V79, P1043, DOI 10.1002-jctb.1072; Ballik I., 2009, CDM INVESTMENT NEWSL; Berge ND, 2007, J ENVIRON ENG-ASCE, V133, P1117, DOI 10.1061-(ASCE)0733-9372(2007)133:12(1117); Berge ND, 2007, WATER RES, V41, P1907, DOI 10.1016-j.watres.2007.01.049; Berge ND, 2006, WASTE MANAGE, V26, P334, DOI 10.1016-j.wasman.2005.11.003; Berge ND, 2005, CRIT REV ENV SCI TEC, V35, P365, DOI 10.1080-10643380590945003; Berge ND, 2009, WASTE MANAGE, V29, P1558, DOI 10.1016-j.wasman.2008.12.010; Bilgili MS, 2012, WASTE MANAGE RES, V30, P161, DOI 10.1177-0734242X11417983; Bilgili MS, 2007, J HAZARD MATER, V143, P177, DOI 10.1016-j.jhazmat.2006.09.012; Bilgili MS, 2007, J HAZARD MATER, V145, P186, DOI 10.1016-j.jhazmat.2006.11.014; Bilgili MS, 2006, ENVIRON MANAGE, V38, P189, DOI 10.1007-s00267-005-0179-1; Borglin SE, 2004, J AIR WASTE MANAGE, V54, P815; Borjesson G, 2000, ENVIRON SCI TECHNOL, V34, P4044, DOI 10.1021-es991350s; Burton SAQ, 1998, WASTE MANAGE RES, V16, P41, DOI 10.1177-0734242X9801600106; Christensen TH, 2001, APPL GEOCHEM, V16, P659, DOI 10.1016-S0883-2927(00)00082-2; Cossu R, 2003, WASTE MANAGE, V23, P37, DOI 10.1016-S0956-053X(02)00147-2; Cossu R., 2005, 10 SARD WAST MAN LAN; Das KC, 2002, ADV ENVIRON RES, V6, P401, DOI 10.1016-S1093-0191(01)00066-1; Ecosystem Marketplace, 2011, BACK FUT BLOOMB NEW; El Fadel M, 2013, WASTE MANAGE RES, V31, P30, DOI 10.1177-0734242X12457118; El-Fadel M., 2001, MUNICIPAL SOLI UNPUB; Environmental Control Systems, 1999, U.S. Patent, Patent No. [5,888,022, 5888022]; Erses AS, 2008, BIORESOURCE TECHNOL, V99, P5418, DOI 10.1016-j.biortech.2007.11.008; Gabr M. A., 2000, GEOTECH NEWS, V28, P50; Gambelin D. J., 1998, 3 ANN SWANA LANDF S; Giannis A, 2008, WASTE MANAGE, V28, P1346, DOI 10.1016-j.wasman.2007.06.024; Boothe DDH, 2001, ADV ENVIRON RES, V5, P285; Hamoda MF, 2006, J ENVIRON SCI HEAL A, V41, P77, DOI 10.1080-10934520500298895; Hanashima M., 1999, P SARD 99 7 INT WAST, P313; Hao YJ, 2010, WASTE MANAGE RES, V28, P1057, DOI 10.1177-0734242X09355182; He PJ, 2011, J ENVIRON SCI-CHINA, V23, P1011, DOI 10.1016-S1001-0742(10)60574-8; He R, 2006, J HAZARD MATER, V136, P784, DOI 10.1016-j.jhazmat.2006.01.008; Heyer KU, 2005, WASTE MANAGE, V25, P353, DOI 10.1016-j.wasman.2005.02.007; Hossain M. S., 2010, Geotechnical and Geological Engineering, V28, DOI 10.1007-s10706-009-9299-3; Hossain MS, 2003, J GEOTECH GEOENVIRON, V129, P1151, DOI 10.1061-(ASCE)1090-0241(2003)129:12(1151); Hudgins M. P., 1999, P SARD 99 7 INT WAST, P327; Huo SL, 2008, WATER SA, V34, P133; Inanc B, 2007, J HAZARD MATER, V141, P793, DOI 10.1016-j.jhazmat.2006.07.042; Inanc B., 2003, 14 ANN S JAP SOC SOL; Intergovernmental Panel on Climate Change, 2007, CLIM CHANG 2007 PHYS; Ishigaki T, 2005, ENVIRON GEOL, V48, P845, DOI 10.1007-s00254-005-0008-0; Ishigaki T., 2003, J SOLID WASTE TECHNO, V29, P230; Jun D, 2007, J HAZARD MATER, V147, P240, DOI 10.1016-j.jhazmat.2007.01.001; Kim H., 2005, THESIS U FLORIDA; Kjeldsen P, 2002, CRIT REV ENV SCI TEC, V32, P297, DOI 10.1080-10643380290813462; Kossoy A., 2010, STATE TRENDS CARBON; Kumar S, 2011, CRIT REV BIOTECHNOL, V31, P77, DOI 10.3109-07388551.2010.492206; Larson D. F., 2008, 4761 WORLD BANK DEV; Lee JY, 2002, ENVIRON GEOL, V42, P945, DOI 10.1007-s00254-002-0599-7; Mackie KR, 2009, ENVIRON MODELL SOFTW, V24, P1223, DOI 10.1016-j.envsoft.2009.04.003; McCreanor PT, 2000, WATER RES, V34, P1285, DOI 10.1016-S0043-1354(99)00243-2; Mehta R, 2002, J ENVIRON ENG-ASCE, V128, P228, DOI 10.1061-(ASCE)0733-9372(2002)128:3(228); Mertoglu B, 2006, PROCESS BIOCHEM, V41, P2359, DOI 10.1016-j.procbio.2006.06.014; Mertoglu B, 2007, J HAZARD MATER, V142, P258, DOI 10.1016-j.jhazmat.2006.08.008; Nikolaou A, 2010, ENVIRON TECHNOL, V31, P1381, DOI 10.1080-09593331003743104; Peterson C, 2009, CDM INVESTMENT NEWSL; Powell J, 2006, ENVIRON SCI TECHNOL, V40, P1029, DOI 10.1021-es051114j; Prantl R, 2006, WASTE MANAGE, V26, P373, DOI 10.1016-j.wasman.2005.11.010; Price GA, 2003, WASTE MANAGE, V23, P675, DOI 10.1016-S0956-053X(03)00104-1; Qiu Z., 2010, 2010 4 INT C BIOINF; Read AD, 2001, WASTE MANAGE, V21, P617, DOI 10.1016-S0956-053X(00)00124-0; Read AD, 2001, GEOGR J, V167, P235, DOI 10.1111-1475-4959.00021; Read AD, 2001, RESOUR CONSERV RECY, V32, P115, DOI 10.1016-S0921-3449(01)00053-2; Reinhart DR, 2002, WASTE MANAGE RES, V20, P172; Rendra S, 2007, ENVIRON TECHNOL, V28, P609, DOI 10.1080-09593332808618822; Rich C, 2008, WASTE MANAGE, V28, P1039, DOI 10.1016-j.wasman.2007.03.022; Ritkowski M., 2003, 9 INT S WAST MAN LAN; Ritzkowski M, 2006, WASTE MANAGE, V26, P356, DOI 10.1016-j.wasman.2005.11.009; Sang NN, 2009, J BIOSCI BIOENG, V108, P336, DOI 10.1016-j.jbiosc.2009.04.019; Sang NN, 2008, J BIOSCI BIOENG, V106, P425, DOI 10.1263-jbb.106.425; Shao LM, 2008, WASTE MANAGE, V28, P1000, DOI 10.1016-j.wasman.2007.02.028; Smith M. C, 2000, ADV ENVIRON RES, V3, P459; Spokas K, 2003, WASTE MANAGE, V23, P599, DOI 10.1016-S0956-053X(03)00102-8; Sponza DT, 2004, PROCESS BIOCHEM, V39, P2157, DOI 10.1016-j.procbio.2003.11.012; STESSEL RI, 1992, WASTE MANAGE RES, V10, P485, DOI 10.1177-0734242X9201000603; Theng L. C, 2005, WASTE MANAGE, V25, P702; Thompson S, 2009, WASTE MANAGE, V29, P2085, DOI 10.1016-j.wasman.2009.02.004; Unnikrishnan, 2010, RESOURCES CONSERVATI, V54, P630; Wang Q, 2006, WASTE MANAGE, V26, P815, DOI 10.1016-j.wasman.2005.10.002; Warith M, 2002, WASTE MANAGE, V22, P7, DOI 10.1016-S0956-053X(01)00014-9; Yazdani R, 2010, ENVIRON SCI TECHNOL, V44, P6215, DOI 10.1021-es1022398; Zhang HH, 2008, ATMOS ENVIRON, V42, P5579, DOI 10.1016-j.atmosenv.2008.03.0100
VHDL-AMS based genetic optimisation of fuzzy logic controllers
No full textPurpose – This paper presents a VHDL-AMS based genetic optimisation methodology for fuzzy logic controllers (FLCs) used in complex automotive systems and modelled in mixed physical domains. A case study applying this novel method to an active suspension system has been investigated to obtain a new type of fuzzy logic membership function with irregular shapes optimised for best performance. Design/methodology/approach – The geometrical shapes of the fuzzy logic membership functions are irregular and optimised using a genetic algorithm (GA). In this optimisation technique, VHDL-AMS is used not only for the modelling and simulation of the FLC and its underlying active suspension system but also for the implementation of a parallel GA directly in the system testbench. Findings – Simulation results show that the proposed FLC has superior performance in all test cases to that of existing FLCs that use regular-shape, triangular or trapezoidal membership functions. Research limitations – The test of the FLC has only been done in the simulation stage, no physical prototype has been made. Originality/value – This paper proposes a novel way of improving the FLC’s performance and a new application area for VHDL-AMS
The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis
No full textPubMedID: 18032542Objectives: To investigate the role of shared epitope (SE) alleles in the short-term clinical response to leflunomide for the treatment of active RA. Methods: In an open-label, multi-centre study of 16-weeks duration, 93 patients (82% female) fulfilling ARA 1987 RA criteria were treated with leflunomide (100 mg loading dose for 3 days, then 20 mg/day as the maintenance dose). The primary efficacy criterion was the response status according to the European League Against Rheumatism (EULAR) response criteria using Disease Activity Score-28 (DAS28) activity measure. SE determinations have been undertaken by polymerase chain reaction and sequence-specific oligonucleotide genotyping methods. Results: The mean (s.d.) Disease Activity Score-28 (DAS28) was 5.1 (1.3) before the treatment, which was significantly decreased after 16 weeks [3.0 (1.1), P < 0.001]. According to the EULAR response criteria, 55 patients (59.1%) were classified as good responders. SE was positive in 51 (54.8%) of the patients, with 13 (13.9%) having SE homozygosity or carrying any two SE alleles. Among SE-positive patients, 68.6% (35/51) were good responders, compared with 47.6% (20/42) in SE negatives (P = 0.04). No difference was present according to SE hetero- or homozygosity (68.4 vs 69.2%). RF was also present significantly more frequently in the SE-positive group compared with negatives (78.4 vs 57.1%, P = 0.03). However, no significant difference was observed in the prevalence of RF positivity in patients with a good clinical response (72.7 vs 63.2%, P = 0.32). Conclusions: The results suggest that HLA-DRB1 SE presence may favourably affect the outcome of leflunomide monotherapy in an unselected group of RA patients with an active disease and naive to leflunomide. © The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.Funding: This study was supported by an unrestricted research grant from Sanofi–Aventis
Increased red cell distribution width level is associatedwith absence of coronary collateral vessels in patients with acute coronary syndromes
No full textPTPN22 gene polymorphism in Takayasu's arteritis
No full textObjective. Takayasu's arteritis (TA) is a chronic, rare granulomatous panarteritis of unknown aetiology involving mainly the aorta and its major branches. In this study, genetic susceptibility to TA has been investigated by screening the functional single nucleotide polymorphism (SNP) of PTPN22 gene encoding the lymphoid-specific protein tyrosine phosphatase. Methods. Totally, 181 patients with TA and 177 healthy controls are genotyped by PCR-RFLP method for the SNP rs2476601 (A/G) of PTPN22 gene. Polymorphic region was amplified by PCR and digested with Xcm I enzyme. Results. Detected frequencies of heterozygous genotype (AG) were 5.1% (9/177) in control group and 3.8% (7/181) in TA group (P = 0.61, odds ratio: 0.75, 95% CI: 0.3, 2.0). No association with angiographic type, vascular involvement or prognosis of TA was observed either. Conclusion. The distribution of PTPN22 polymorphism did not reveal any association with TA in Turkey. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.SAG-YYP/0007-15/01/ 2007 British Association for PsychopharmacologyFunding: The study is supported by Marmara University Scientific Research Fund (BAPKO) (project no: SAG-YYP/0007-15/01/ 2007) and Istanbul University Research Fund (BAP). -
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database
No full textOBJECTIVES: Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality.
METHODS: The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics.
RESULTS: In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2%), calcium channel blockers (52.7%), and corticosteroids (45.3%) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc.
CONCLUSIONS: The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
No full textObjective To determine the independent impact of different definitions of remission and low disease activity (LDA) on damage accrual. Methods Patients with ≥2 annual assessments from a longitudinal multinational inception lupus cohort were studied. Five mutually exclusive disease activity states were defined: remission off-treatment: clinical Systemic Lupus Erythematosus Disease Activity Index (cSLEDAI)-2K=0, without prednisone or immunosuppressants; remission on-treatment: cSLEDAI-2K score=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; low disease activity Toronto cohort (LDA-TC): cSLEDAI-2K score of ≤2, without prednisone or immunosuppressants; modified lupus low disease activity (mLLDAS): Systemic Lupus Erythematosus Disease Activity Index-2K score of 4 with no activity in major organ/systems, no new disease activity, prednisone ≤7.5 mg/day and/or maintenance immunosuppressants; active: all remaining visits. Only the most stringent definition was used per visit. Antimalarials were allowed in all. The proportion of time that patients were in a specific state at each visit since cohort entry was determined. Damage accrual was ascertained with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Univariable and multivariable generalised estimated equation negative binomial regression models were used. Time-dependent covariates were determined at the same annual visit as the disease activity state but the SDI at the subsequent visit. Results There were 1652 patients, 1464 (88.6%) female, mean age at diagnosis 34.2 (SD 13.4) years and mean follow-up time of 7.7 (SD 4.8) years. Being in remission off-treatment, remission on-treatment, LDA-TC and mLLDAS (per 25% increase) were each associated with a lower probability of damage accrual (remission off-treatment: incidence rate ratio (IRR)=0.75, 95% CI 0.70 to 0.81; remission on-treatment: IRR=0.68, 95% CI 0.62 to 0.75; LDA: IRR=0.79, 95% CI 0.68 to 0.92; and mLLDAS: IRR=0.76, 95% CI 0.65 to 0.89)). Conclusions Remission on-treatment and off-treatment, LDA-TC and mLLDAS were associated with less damage accrual, even adjusting for possible confounders and effect modifiers.Funding text 1: These analyses were supported by a grant from the Universidad Cient\u00EDfica del Sur. Other sources of funding supported activities at individual Systemic Lupus International Collaborating Clinics sites: CG is supported by Lupus UK, Sandwell and West Birmingham Hospitals NHS Trust and the National Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility. The views expressed are those of the authors(s) and not necessarily those of the NHS, the NIHR or the Department of Health. S-CB\u2019s work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1A6A1A03038899). AEC holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. PRF holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Universite Laval. DAI and AR are supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. INB is a National Institute for Health Research (NIHR) senior investigator and is supported by Arthritis Research UK, the NIHR Manchester Biomedical Centre and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. The Hopkins Lupus Cohort is supported by NIH (grant AR43727 and 69572). RR-G\u2019s work was supported by NIH (grants 5UL1TR001422-02, formerly 8UL1TR000150 and UL-1RR- 025741, K24-AR- 02318, and P60AR064464, formerly P60-AR- 48098). MAD\u2019s work was supported by NIH grant RR00046. GR-I is supported by the Department of Education, Universities and Research of the Basque Government. SJ is supported by the Danish Rheumatism Association (A3865) and the Novo Nordisk Foundation (A05990). SL\u2019s work was supported, in part, by the Centers for Disease Control and Prevention (grant U01DP005119); Funding text 2: These analyses were supported by a grant from the Universidad Cient\u00EDfica del Sur. Other sources of funding supported activities at individual Systemic Lupus International Collaborating Clinics sites: CG is supported by Lupus UK, Sandwell and West Birmingham Hospitals NHS Trust and the National Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility. The views expressed are those of the authors(s) and not necessarily those of the NHS, the NIHR or the Department of Health. S-CB\u2019s work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1A6A1A03038899). AEC holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. PRF holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Universit\u00E9 Laval. DAI and AR are supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. INB is a National Institute for Health Research (NIHR) senior investigator and is supported by Arthritis Research UK, the NIHR Manchester Biomedical Centre and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. The Hopkins Lupus Cohort is supported by NIH (grant AR43727 and 69572). RR-G\u2019s work was supported by NIH (grants 5UL1TR001422-02, formerly 8UL1TR000150 and UL-1RR-025741, K24-AR-02318, and P60AR064464, formerly P60-AR-48098). MAD\u2019s work was supported by NIH grant RR00046. GR-I is supported by the Department of Education, Universities and Research of the Basque Government. SJ is supported by the Danish Rheumatism Association (A3865) and the Novo Nordisk Foundation (A05990). SL\u2019s work was supported, in part, by the Centers for Disease Control and Prevention (grant U01DP005119).; Funding text 3: All the following relationships are outside the submitted work. MF-UG: research support from Janssen and Pfizer. CG: consulting fees from the AbbVie, Amgen, AstraZeneca, Centers for Disease Control, Morton Grove Pharmaceutical (MGP), Sanofi and UCB. AEC: consulting fees from AstraZeneca, Bristol Myers Squibb, Exagen Diagnostics and GlaxoSmithKline. DAI: consulting fees from Amgen, Merck Serono, AstraZeneca and Eli Lilly (the honoraria are passed onto a local arthritis charity). AR: consulting fees from Lilly. PRF: participation on advisory boards from AbbVie, AstraZeneca and Lilly. MAK: consulting fees from GSK. MI: consulting fees from AbbVie, UCB, Novartis, Janssen and Lilly
Integrated genomic characterization of endometrial carcinoma
No full textWe performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumours and ~25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent TP53 mutations. Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS and novel mutations in the SWI/SNF chromatin remodelling complex gene ARID5B. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in POLE. Our results classified endometrial cancers into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours.National Institutes of Health (U.S.) (Grant 5U24CA143799-04)National Institutes of Health (U.S.) (Grant 5U24CA143835-04)National Institutes of Health (U.S.) (Grant 5U24CA143840-04)National Institutes of Health (U.S.) (Grant 5U24CA143843-04)National Institutes of Health (U.S.) (Grant 5U24CA143845-04)National Institutes of Health (U.S.) (Grant 5U24CA143848-04)National Institutes of Health (U.S.) (Grant 5U24CA143858-04)National Institutes of Health (U.S.) (Grant 5U24CA143866-04)National Institutes of Health (U.S.) (Grant 5U24CA143867-04)National Institutes of Health (U.S.) (Grant 5U24CA143882-04)National Institutes of Health (U.S.) (Grant 5U24CA143883-04)National Institutes of Health (U.S.) (Grant 5U24CA144025-04)National Institutes of Health (U.S.) (Grant U54HG003067-11)National Institutes of Health (U.S.) (Grant U54HG003079-10)National Institutes of Health (U.S.) (Grant U54HG003273-10
